Drugs / CSF-1 Component #1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03885011 Comparator | Feb → Jul 2019 | presbyopia | Orasis Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSF-1 Component #1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03885011 ↗ |
| Route | Other | “dose twice a day in both eyes with a single drop” NCT03885011 ↗ |